Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients ...
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Yahoo! Finance
oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled "Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021," was published in the International Journal of Cancer and highlights the potential benefits of early use of liver-directed therapies, including chemosaturation (also known as percutaneous hepatic perfusion or PHP), in achieving long-term survival for patients with metastatic uveal melanoma (mUM) and liver metastases. The analysis underscores PHP's advantages in disease control compared to other therapies, supporting its early integration potentially ahead of systemic options or in combination with systemic therapies. The retrospective analysis evaluated 167 patients with mUM who developed liver metastases between 2005 and 2021, focusi
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaBusiness Wire
- Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]Yahoo! Finance
DCTH
Earnings
- 11/4/25 - In-Line
DCTH
Sec Filings
- 11/25/25 - Form 4
- 11/20/25 - Form 8-K
- 11/13/25 - Form 4
- DCTH's page on the SEC website